D0904 - A Pilot Study of Bevacizumab (Avastin) in Patients With Unresectable or Recurrent Hemangioblastoma From Von Hippel-Lindau Disease.
Phase of Trial: Phase 0
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Bevacizumab (Primary)
- Indications Haemangioblastoma
- Focus Therapeutic Use
- 10 May 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 May 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.